This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
3 MedTech Stocks Benefiting From Favorable Product Mix Shifts
by Indrajit Bandyopadhyay
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
BSXNegative Net Change ANGONegative Net Change MDTNegative Net Change
medical medical-devices
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
by Zacks Equity Research
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
FOLDPositive Net Change ADMANegative Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon
by Zacks Equity Research
AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Brookdale Senior 4Q25 Sneak Peek: Occupancy Volume Rises to 82.5%
by Zacks Equity Research
BKD's 4Q25 weighted average occupancy rises to 82.5%, capping a year of gains as resident fees climb.
BSXNegative Net Change UHSNegative Net Change BKDNegative Net Change ENSGPositive Net Change
medical
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
by Zacks Equity Research
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
NVDANegative Net Change VCYTPositive Net Change CDNANegative Net Change NTRAPositive Net Change
medical medical-devices
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
by Ahan Chakraborty
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Are Options Traders Betting on a Big Move in Varex Imaging Stock?
by Zacks Equity Research
Investors need to pay close attention to VREX stock based on the movements in the options market lately.
VREXPositive Net Change
medical
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?
by Sundeep Ganoria
ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.
AZNPositive Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Is the Options Market Predicting a Spike in U.S. Physical Therapy Stock?
by Zacks Equity Research
Investors need to pay close attention to USPH stock based on the movements in the options market lately.
USPHPositive Net Change
medical
Health & Fitness Stocks Positioned for Strong 2026 Growth
by Nilanjan Choudhury
UNFI, COCO, DOCS and PTON are tapping into the $11T wellness boom with tech, nutrition, and fitness-driven growth.
AMZNNegative Net Change AAPLNegative Net Change COCONegative Net Change UNFIPositive Net Change PTONPositive Net Change DOCSNegative Net Change
consumer-discretionary consumer-staples medical
Implied Volatility Surging for CareDx Stock Options
by Zacks Equity Research
Investors need to pay close attention to CareDx stock based on the movements in the options market lately.
CDNANegative Net Change
medical medical-devices
Should You Buy, Sell or Hold TLRY Stock Post Q2 Earnings?
by Moumi Mondal
Tilray Brands posts record Q2 revenue of $217.5M, beats sales estimates, reaffirms EBITDA outlook as international cannabis and distribution offset beverage weakness.
CGCPositive Net Change TLRYPositive Net Change ACBNo Net Change
medical medical-devices
TEM's Collab for Oncology Patient Population Is Gaining Attention
by Sridatri Sarkar
Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care.
ILMNPositive Net Change MYGNNegative Net Change TEMNegative Net Change
medical
New Strong Buy Stocks for January 13th
by Zacks Equity Research
KNOP, OESX, LAND, FET and SLNO have been added to the Zacks Rank #1 (Strong Buy) List on Jan.13, 2026.
FETPositive Net Change KNOPPositive Net Change OESXPositive Net Change LANDPositive Net Change SLNONegative Net Change
medical oil-energy reit
New Strong Sell Stocks for Jan. 13
by Zacks Equity Research
ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
BZHPositive Net Change ATAINegative Net Change BHRNegative Net Change
medical
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
by Zacks Equity Research
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
FOLDPositive Net Change CRMDPositive Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Implied Volatility Surging for Ardent Health Stock Options
by Zacks Equity Research
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
ARDTNegative Net Change
medical
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
by Zacks Equity Research
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
FOLDPositive Net Change PCRXNegative Net Change CRMDPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
by Zacks Equity Research
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
TEVANegative Net Change RPRXPositive Net Change CRMDPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Hims & Hers Expands Platform-Led Access to Provider-Directed Care
by Debanjana Dey
HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.
MEDPositive Net Change GDRXNegative Net Change HIMSPositive Net Change
medical medical-devices
GeneDx Partners With Komodo Health to Advance Rare Disease Research
by Zacks Equity Research
WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change WGSNegative Net Change
medical medical-devices
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
by Zacks Equity Research
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
RHHBYNegative Net Change EXELPositive Net Change FOLDPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
by Zacks Equity Research
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
INSMNegative Net Change CRMDPositive Net Change KROSPositive Net Change
biotechs medical
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
by Zacks Equity Research
Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.
CRLPositive Net Change VCYTPositive Net Change CDNANegative Net Change RVTYPositive Net Change
medical medical-devices
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
by Santanu Roy
Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.
ACNNegative Net Change MMMPositive Net Change SBUXPositive Net Change FORMNegative Net Change ULTAPositive Net Change HIIPositive Net Change AMKRPositive Net Change MTDNegative Net Change FIVENegative Net Change NOBLPositive Net Change FIGSPositive Net Change INDVNegative Net Change
aerospace computers medical medical-devices multi-sector-conglomerates restaurants retail semiconductor